TNFSF10 and pancreatic neoplasm: In recent years, the administration of agonistic antibodies targeting the receptors for TNF-related apoptosis-inducing ligand (TRAIL) has pre-clinically been demonstrated to represent a promising therapeutic avenue, which is at this time undergoing clinical investigation in numerous tumor entities including pancreatic cancer [2]–[6].